Esperion Therapeutics Balance Sheet Health
Financial Health criteria checks 1/6
Esperion Therapeutics has a total shareholder equity of $-344.2M and total debt of $262.5M, which brings its debt-to-equity ratio to -76.3%. Its total assets and total liabilities are $352.3M and $696.5M respectively. Esperion Therapeutics's EBIT is $4.9M making its interest coverage ratio 0.1. It has cash and short-term investments of $189.3M.
Key information
-76.3%
Debt to equity ratio
US$262.48m
Debt
| Interest coverage ratio | 0.1x |
| Cash | US$189.30m |
| Equity | -US$344.22m |
| Total liabilities | US$696.54m |
| Total assets | US$352.32m |
Recent financial health updates
No updates
Recent updates
Esperion Therapeutics: Strategically Positioned To Grow
Aug 16Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
May 20A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Jan 20Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
Oct 27Esperion: Hunting Big Game In The Danger Zone
Aug 05Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year
May 09Financial Position Analysis
Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESPR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ESPR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.